PCSA · NASDAQ
Processa Pharmaceuticals (PCSA) Stock Price & Fundamentals
Processa Pharmaceuticals (PCSA) closed at $1,002.56 on Oct 9, 2026, up 0.56% from the previous close of $996.93.
Share price, past year
1Y −3.66%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,002.56 |
| Sep 30, 2026 | $1,044.58 |
| Aug 31, 2026 | $1,149.42 |
| Jul 31, 2026 | $1,131.54 |
| Jun 30, 2026 | $1,137.88 |
| May 29, 2026 | $1,179.94 |
| Apr 30, 2026 | $1,186.52 |
| Mar 31, 2026 | $1,174.43 |
| Feb 27, 2026 | $1,133.57 |
| Jan 30, 2026 | $1,086.93 |
| Dec 31, 2025 | $1,096.98 |
| Nov 28, 2025 | $1,135.66 |
| Oct 31, 2025 | $1,064.54 |
Key statistics
- Market cap
- $2.80B
- P/E (TTM)
- 1,002.6
- EPS (TTM)
- $1.00
- Revenue (TTM)
- —
- Net income (TTM)
- −$13.44M
- Shares outstanding
- 2.8M
- Dividend yield
- —
- 52-week range
- $996.93 – $1,202.10
Processa Pharmaceuticals's market cap is $2.80B, based on a share price of $1,002.56 and 2.8M shares outstanding as of Jun 30, 2026.
Financials
Processa Pharmaceuticals reported revenue of $0.00 for fiscal 2022.
Processa Pharmaceuticals reported a net loss of $13.56M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $0.00 | — | −$27.42M | — | −$34.05 | — |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$11.43M | — | −$0.75 | — |
| FY2016ended Dec 31, 2016 | $5.00K | −95.6% | −$1.92M | −38,341.3% | −$0.07 | −$2.18M |
| FY2015ended Dec 31, 2015 | $113.43K | +5.8% | — | — | — | −$873.31K |
| FY2014ended Dec 31, 2014 | $107.24K | −65.7% | — | — | — | −$2.70M |
| FY2013ended Dec 31, 2013 | $312.48K | +62.6% | — | — | — | −$2.57M |
| FY2012ended Dec 31, 2012 | $192.15K | — | — | — | — | −$2.23M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q1 FY2022ended Mar 31, 2022 | $0.00 | — | — |
| Q1 FY2016ended Mar 31, 2016 | $5.00K | — | — |
| Q3 FY2015ended Sep 30, 2015 | $58.17K | — | — |
| Q2 FY2015ended Jun 30, 2015 | $20.04K | — | — |
| Q1 FY2015ended Mar 31, 2015 | $37.76K | — | — |
| Q3 FY2014ended Sep 30, 2014 | $52.62K | — | — |
| Q2 FY2014ended Jun 30, 2014 | $112.84K | — | — |
Company profile
- Name
- Processa Pharmaceuticals, Inc.
- Ticker
- PCSA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 601 21st Street, Suite 300, Vero Beach, FL 32960
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001533743
Recent SEC filings
- Aug 14, 2026
- Aug 4, 2026
- Jul 29, 2026
- May 7, 2026
- Apr 30, 2026
- Apr 30, 2026
- Mar 18, 2026
- Feb 19, 2026
Frequently asked questions
What is Processa Pharmaceuticals's stock price?
Processa Pharmaceuticals (PCSA) closed at $1,002.56 on Oct 9, 2026, up 0.56% from the previous close of $996.93.
What is Processa Pharmaceuticals's market cap?
Processa Pharmaceuticals's market cap is $2.80B, based on a share price of $1,002.56 and 2.8M shares outstanding as of Jun 30, 2026.
How much revenue does Processa Pharmaceuticals make?
Processa Pharmaceuticals reported revenue of $0.00 for fiscal 2022.
What is PCSA's P/E ratio?
Processa Pharmaceuticals's price-to-earnings ratio is 1,002.6, based on trailing twelve-month diluted EPS of $1.00.
Does Processa Pharmaceuticals pay a dividend?
Processa Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Processa Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures